Aadi Bioscience, Inc. (AADI)
NASDAQ: AADI · Real-Time Price · USD
2.880
0.00 (0.00%)
Jan 31, 2025, 4:00 PM EST - Market closed

Company Description

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes.

Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.

The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway.

Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Aadi Bioscience, Inc.
Aadi Bioscience logo
Country United States
Founded 2011
Industry Biotechnology
Sector Healthcare
Employees 89
CEO David Lennon

Contact Details

Address:
17383 Sunset Boulevard, Suite A250
Pacific Palisades, California 90272
United States
Phone 424 744 8055
Website aadibio.com

Stock Details

Ticker Symbol AADI
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001422142
CUSIP Number 00032Q104
ISIN Number US00032Q1040
Employer ID 61-1547850
SIC Code 2834

Key Executives

Name Position
David J. Lennon Ph.D. President, Chief Executive Officer and Director
Scott M. Giacobello CPA Chief Financial Officer, Treasurer, Investor Relations and Corporate Communications
Stephen M. Rodin J.D. Senior Vice President of Legal and General Counsel
Raymond G. Steitz Senior Vice President of Human Resources and Chief Human Resources Officer
Bryan Ball Chief Technical Operations Officer

Latest SEC Filings

Date Type Title
Jan 31, 2025 DEFM14A Filing
Jan 30, 2025 SCHEDULE 13D Filing
Jan 29, 2025 SCHEDULE 13G Filing
Jan 24, 2025 SCHEDULE 13D/A Filing
Jan 21, 2025 PREM14A Filing
Dec 31, 2024 SCHEDULE 13D Filing
Dec 30, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Dec 23, 2024 SCHEDULE 13D/A Filing
Dec 23, 2024 SCHEDULE 13D/A Filing
Dec 20, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material